复星医药(02196)：复迈宁新增适应症上市申请获受理并获纳入优先审评程序

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received acceptance from the National Medical Products Administration for the marketing application of Fumainin® (generic name: Luwotimab Tablets) for the treatment of symptomatic, unresectable plexiform neurofibromas (PN) in adult patients with Neurofibromatosis type 1 (NF1), and it has been included in the priority review process [1] Group 1 - The drug Fumainin® is developed for a new indication targeting adult patients with NF1 [1] - The application has been accepted by the National Medical Products Administration, indicating regulatory progress [1] - The inclusion in the priority review process may expedite the approval timeline for the drug [1]